These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 27299299)

  • 1. Mathematical modeling of erythrocyte chimerism informs genetic intervention strategies for sickle cell disease.
    Altrock PM; Brendel C; Renella R; Orkin SH; Williams DA; Michor F
    Am J Hematol; 2016 Sep; 91(9):931-7. PubMed ID: 27299299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease.
    Park SH; Lee CM; Dever DP; Davis TH; Camarena J; Srifa W; Zhang Y; Paikari A; Chang AK; Porteus MH; Sheehan VA; Bao G
    Nucleic Acids Res; 2019 Sep; 47(15):7955-7972. PubMed ID: 31147717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimerism and cure: hematologic and pathologic correction of murine sickle cell disease.
    Kean LS; Manci EA; Perry J; Balkan C; Coley S; Holtzclaw D; Adams AB; Larsen CP; Hsu LL; Archer DR
    Blood; 2003 Dec; 102(13):4582-93. PubMed ID: 12933586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype.
    Brendel C; Guda S; Renella R; Bauer DE; Canver MC; Kim YJ; Heeney MM; Klatt D; Fogel J; Milsom MD; Orkin SH; Gregory RI; Williams DA
    J Clin Invest; 2016 Oct; 126(10):3868-3878. PubMed ID: 27599293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing.
    Wen J; Tao W; Hao S; Zu Y
    J Hematol Oncol; 2017 Jun; 10(1):119. PubMed ID: 28610635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene replacement therapy for sickle cell disease and other blood disorders.
    Townes TM
    Hematology Am Soc Hematol Educ Program; 2008; ():193-6. PubMed ID: 19074080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction.
    Perumbeti A; Higashimoto T; Urbinati F; Franco R; Meiselman HJ; Witte D; Malik P
    Blood; 2009 Aug; 114(6):1174-85. PubMed ID: 19474450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of mixed hematopoietic chimerism in a mouse model of bone marrow transplantation for sickle cell anemia.
    Iannone R; Luznik L; Engstrom LW; Tennessee SL; Askin FB; Casella JF; Kickler TS; Goodman SN; Hawkins AL; Griffin CA; Noffsinger L; Fuchs EJ
    Blood; 2001 Jun; 97(12):3960-5. PubMed ID: 11389040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systems pharmacology model for gene therapy in sickle cell disease.
    Zheng B; Wille L; Peppel K; Hagen D; Matteson A; Ahlers J; Schaff J; Hua F; Yuraszeck T; Cobbina E; Apgar JF; Burke JM; Roberts J; Das R
    CPT Pharmacometrics Syst Pharmacol; 2021 Jul; 10(7):696-708. PubMed ID: 34139105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of an anti-sickling beta-globin in human erythroblasts derived from retrovirally transduced primitive normal and sickle cell disease hematopoietic cells.
    Oh IH; Fabry ME; Humphries RK; Pawliuk R; Leboulch P; Hoffman R; Nagel RL; Eaves C
    Exp Hematol; 2004 May; 32(5):461-9. PubMed ID: 15145214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT.
    Fitzhugh CD; Cordes S; Taylor T; Coles W; Roskom K; Link M; Hsieh MM; Tisdale JF
    Blood; 2017 Oct; 130(17):1946-1948. PubMed ID: 28887325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amelioration of murine sickle cell disease by nonablative conditioning and γ-globin gene-corrected bone marrow cells.
    Pestina TI; Hargrove PW; Zhao H; Mead PE; Smeltzer MP; Weiss MJ; Wilber A; Persons DA
    Mol Ther Methods Clin Dev; 2015; 2():15045. PubMed ID: 26665131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vivo HSC Gene Therapy Using a Bi-modular HDAd5/35++ Vector Cures Sickle Cell Disease in a Mouse Model.
    Li C; Wang H; Georgakopoulou A; Gil S; Yannaki E; Lieber A
    Mol Ther; 2021 Feb; 29(2):822-837. PubMed ID: 32949495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic strategies for the treatment of sickle cell anaemia.
    Mansilla-Soto J; Rivière I; Sadelain M
    Br J Haematol; 2011 Sep; 154(6):715-27. PubMed ID: 21707580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-clinical Development of a Lentiviral Vector Expressing the Anti-sickling βAS3 Globin for Gene Therapy for Sickle Cell Disease.
    Poletti V; Urbinati F; Charrier S; Corre G; Hollis RP; Campo Fernandez B; Martin S; Rothe M; Schambach A; Kohn DB; Mavilio F
    Mol Ther Methods Clin Dev; 2018 Dec; 11():167-179. PubMed ID: 30533448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility of using autologous transplantation to evaluate hematopoietic stem cell-based gene therapy strategies in transgenic mouse models of human disease.
    Miller CL; Imren S; Antonchuk J; Kalberer C; Fabry ME; Nagel RL; Humphries RK; Eaves CJ
    Mol Ther; 2002 Sep; 6(3):422-8. PubMed ID: 12231180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene Therapy as the New Frontier for Sickle Cell Disease.
    Garg H; Tatiossian KJ; Peppel K; Kato GJ; Herzog E
    Curr Med Chem; 2022; 29(3):453-466. PubMed ID: 34047257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. β-Globin sleeping beauty transposon reduces red blood cell sickling in a patient-derived CD34(+)-based in vitro model.
    Sjeklocha LM; Wong PY; Belcher JD; Vercellotti GM; Steer CJ
    PLoS One; 2013; 8(11):e80403. PubMed ID: 24260386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correction of sickle cell disease in transgenic mouse models by gene therapy.
    Pawliuk R; Westerman KA; Fabry ME; Payen E; Tighe R; Bouhassira EE; Acharya SA; Ellis J; London IM; Eaves CJ; Humphries RK; Beuzard Y; Nagel RL; Leboulch P
    Science; 2001 Dec; 294(5550):2368-71. PubMed ID: 11743206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene Addition Strategies for β-Thalassemia and Sickle Cell Anemia.
    Dong AC; Rivella S
    Adv Exp Med Biol; 2017; 1013():155-176. PubMed ID: 29127680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.